Antibody Targeted Virus Particles For A Gene Therapy Approach To Inhibiting Atheroschlerosis Development
Funder
National Health and Medical Research Council
Funding Amount
$95,313.00
Summary
I am a Biotechnologist and my research looks into ways of preventing Atherosclerosis. Atherosclerosis is the build up of plaques in artery walls, and is the major precursor condition to stroke and myocardial infarction (heart attack). My project focuses on a preventative gene therapy which will be delivered specifically to early stage plaques. The gene will inhibit one of the earliest developmental stages of atherosclerosis: recruitment of immune cells to these sites, and so prevent their growth ....I am a Biotechnologist and my research looks into ways of preventing Atherosclerosis. Atherosclerosis is the build up of plaques in artery walls, and is the major precursor condition to stroke and myocardial infarction (heart attack). My project focuses on a preventative gene therapy which will be delivered specifically to early stage plaques. The gene will inhibit one of the earliest developmental stages of atherosclerosis: recruitment of immune cells to these sites, and so prevent their growth.Read moreRead less
The Use Of Real-World Evidence To Support Regulatory And Reimbursement Decisions
Funder
National Health and Medical Research Council
Funding Amount
$91,538.00
Summary
Traditionally, medicines are studied extensively in clinical trials before they are widely available. More recently, some medicines have been allowed to enter the market without complete data on their benefits and risks. This means that these issues can only be studied once a medicine is on the market and used in routine clinical practice; this is referred to as real-world evidence. This research evaluates if this evidence is sufficient to prove that a medicine is safe and that it works
Lung cancer is the commonest cause of cancer death worldwide. There is growing interest in the genetic causes of lung cancer. The overall aim of this research is to gain a better understanding of the steps in the genetic pathway of lung cancer spread. This knowledge is essential in the development of new targeted therapies and improvement in lung cancer prognosis.
Optimising Cooperative Group Cancer Clinical Trials In The Era Of Molecularly Targeted Treatments
Funder
National Health and Medical Research Council
Funding Amount
$55,778.00
Summary
Cancer treatments are tested in trials to ensure that they are effective and safe for use. Recently treatments have been developed that act on newly discovered pathways of cancer growth. I aim to research the way cancer clinical trials are designed and evaluate ways to improve them. This will help to ensure cancer medicines are brought into clinical use as efficiently as possible in this new era of drug treatment.
Novel Inhibition Of Cancer Cell Growth In Gastrointestinal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$47,474.00
Summary
This research project will focus on new treatment targets for gastrointestinal malignancies, focusing on the mTOR pathway which is important in driving cancer cell growth. The mTOR inhibitor drug Everolimus will be used in colon and biliary tract cancers to look for novel biomarkers of response and resistance to treatment, using cancer cell lines and correlative analysis with data obtained from patients' tumour samples and clinical assessment in current trials.
A New Therapeutic Monoclonal Antibody Targeting CD302 In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This project will develop a new antibody treatment for Acute Myeloid Leukaemia. Antibody treatments help the body to attack the leukaemia using its immune system. The prognosis of this leukaemia is poor. Our current treatments use high dose chemotherapy and sometimes a stem cell transplant. Many patients cannot have the current therapy due to their age or other medical problems. A new antibody therapy may be used on its own or with other therapies to help more patients achieve remission.
Understanding The Molecular Basis Of Inherent And Acquired Resistance To Targeted Therapies In Metastatic Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$107,750.00
Summary
Targeted therapies aim to block cancer growth by interfering with specific molecules needed for its development and progression. Targeted therapies have led to improved responses and survival in patients with metastatic colorectal cancer. However, not all patients benefit from these treatments, and most patients who do respond eventually develop resistance. The aim of this research is to understand the mechanisms of resistance to these treatments, in order to improve their use in patients.
Investigating Stakeholder Experiences In Implementing And Adopting Genome Sequencing In Paediatric Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$91,538.00
Summary
Medicare funding became available for genome sequencing in 2020. Paediatricians can now order this test to help diagnose childhood syndromes. Expanding testing beyond genetics services is vital for patients to benefit broadly, but paediatricians and other medical specialists are known to feel ill-prepared to assume a greater role. My PhD project will investigate what we can learn from paediatric stakeholder experiences in delivering genome sequencing to aid future adoption in other settings.
Optimising Management Of Injection-related Infections In People Who Inject Drugs
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
People who inject drugs are a vulnerable group who are at increased risk of bacterial infections, which can lead to serious illness and death. This project aims to optimize management of bacterial infections in people who inject drugs. Measuring the current burden of infections, analysing different management strategies employed in hospitals and discussing attitudes and barriers to care with both healthcare workers and people who inject drugs will provide the evidence to optimize ongoing care.
Provision Of Best Practice Care To Aboriginal And Torres Strait Islander Children With Burn Injuries.
Funder
National Health and Medical Research Council
Funding Amount
$68,946.00
Summary
This project will develop best practice guidelines for burns care of Aboriginal and Torres Strait Islander children by consulting medical experts and parents/carers of Aboriginal and Torres Strait Islander children admitted to a public hospital due to burn injuries. These guidelines will be used to explore the care provided to Aboriginal and Torres Strait Islander children and barriers or enablers experienced by them and medical experts in receiving/providing high-quality, culturally safe care.